⚠ Evidence warning: Clinical trials or other evidence do not support the claim that a sustained strict gluten-free diet reduces the lymphoma risk in dermatitis herpetiformis to background levels. This page keeps it as a report of what people, websites or other media say.

Dermatitis Herpetiformis

Dermatitis herpetiformis (DH) is an intensely itchy, chronic blistering skin disease caused by gluten sensitivity — the same immune mechanism that drives celiac disease. Although it presents on the skin, it is fundamentally a systemic autoimmune condition in which ingested gluten triggers immunoglobulin A (IgA) antibody deposits in the dermis, igniting blisters on the elbows, knees, buttocks, and scalp. A strict gluten-free diet is both the primary treatment and the only therapy that addresses the underlying disease rather than masking its symptoms.

Table of Contents

  1. Dermatitis Herpetiformis Explained
  2. Pathophysiology: The Gluten-IgA Connection
  3. Epidemiology and Risk Factors
  4. Clinical Features and Symptoms
  5. Diagnostic Approach
  6. Treatment: Gluten-Free Diet and Dapsone
  7. Monitoring and Long-Term Management
  8. Key Research Papers
  9. Related PubMed Searches
  10. Connections
  11. Featured Videos

Dermatitis Herpetiformis Explained

Dermatitis herpetiformis is the pathognomonic cutaneous manifestation of celiac disease — the skin expression of gluten-sensitive enteropathy. First described by Louis Duhring in 1884, it was long considered a purely dermatological condition until the 1960s and 1970s, when researchers established its inseparable connection to intestinal gluten intolerance and small bowel villous atrophy.

Despite its name, DH has no relationship to herpes viruses. The term "herpetiformis" refers only to the appearance of grouped (herpetiform) vesicles, which mimic the cluster pattern of herpesvirus skin lesions. The cause is entirely immunological, driven by gluten consumption in genetically susceptible individuals.

DH is classified as an autoimmune bullous (blistering) dermatosis. Unlike many other blistering diseases that affect the skin in isolation, DH reflects systemic gluten intolerance — meaning most patients have concurrent intestinal damage even when they have no digestive symptoms whatsoever. Treating only the skin without addressing the diet leaves the underlying celiac disease active and the patient at continued risk for long-term complications.

Back to Table of Contents

Pathophysiology: The Gluten-IgA Connection

The mechanism linking dietary gluten to skin blistering involves a multi-step autoimmune cascade that operates across both the gut and the skin simultaneously.

Step 1 — Gluten sensitization: In genetically susceptible individuals (those carrying HLA-DQ2 or HLA-DQ8 haplotypes), dietary gluten — specifically the gliadin component of wheat, rye, and barley — is incompletely digested in the small intestine. Tissue transglutaminase 2 (TG2) in the gut wall deamidates gliadin peptides, creating epitopes that are recognized as foreign by antigen-presenting cells bearing HLA-DQ2 or HLA-DQ8.

Step 2 — Dual antibody production: The adaptive immune response generates immunoglobulin A antibodies against two closely related enzyme targets. Anti-tissue transglutaminase 2 (anti-TG2) antibodies cause intestinal damage — the same antibodies found in classic celiac disease. Critically, the immune response also cross-reacts with epidermal transglutaminase 3 (TG3, eTG), a structurally related enzyme expressed in the skin. Anti-TG3 immunoglobulin A antibodies are the skin-specific autoantibody of DH and are the most diagnostically specific serum marker for this condition.

Step 3 — Dermal immunoglobulin A deposition: IgA-TG3 immune complexes circulate in the bloodstream and deposit in the papillary dermis — the uppermost layer of the dermis just beneath the epidermis, where small capillaries and collagen bundles project upward into the epidermal folds (dermal papillae). This deposition occurs at the tips of the dermal papillae and is independent of whether the skin is visibly inflamed.

Step 4 — Complement activation and neutrophil infiltration: The immunoglobulin A deposits activate complement via the alternative and lectin pathways, generating chemotactic fragments (C3a, C5a) that recruit neutrophils into the papillary dermis. Neutrophil accumulation at papillary tips releases proteolytic enzymes (including elastase and collagenase) that cleave the dermoepidermal junction, producing subepidermal fluid-filled blisters.

Key insight: The skin lesions are driven by the same gluten intake that damages the intestinal mucosa. Gluten elimination depletes the antigenic stimulus, stops new immunoglobulin A complex formation, and eventually allows existing deposits to clear — explaining why the gluten-free diet is the only true disease-modifying treatment.

Back to Table of Contents

Epidemiology and Risk Factors

DH has a pronounced Northern European predominance, reflecting the distribution of HLA-DQ2 and DQ8 haplotypes. In Finland — one of the most studied populations — a 40-year study from Tampere counted 75.3 people with DH per 100,000 in 2009, eight times fewer than people with celiac disease in the same area. In the United States the prevalence is estimated at approximately 1 in 10,000, though this likely underestimates true frequency due to underdiagnosis and delayed diagnosis averaging 10 or more years from symptom onset.

Sex distribution: Unlike celiac disease, which is approximately twice as common in women, DH shows roughly equal sex distribution, with some studies suggesting a slight male predominance; the Finnish 40-year study found a male-to-female ratio of 1.1 to 1. The reason for this difference is not fully understood but may relate to sex differences in skin immunoglobulin A trafficking.

Age of onset: DH can occur at any age. The average age at diagnosis has risen in recent decades: a 2018 review puts it at 40–50 years today, and in the Finnish 40-year study it rose in men from 35.3 to 51.1 years and in women from 36.3 to 45.8 years. Pediatric DH is recognized but uncommon. Late-onset DH in elderly patients is increasingly reported.

Genetic risk factors:

Associated autoimmune conditions: DH clusters with other organ-specific autoimmune diseases, consistent with shared human leukocyte antigen (HLA) haplotypes and immune dysregulation:

Dietary triggers beyond classic gluten: Iodine intake can transiently worsen DH skin disease in some patients, possibly by exacerbating neutrophil recruitment at existing immunoglobulin A deposits, though iodine restriction is not routinely recommended. Oats represent a nuanced case — most DH patients can tolerate certified gluten-free oats once the disease is well controlled on a gluten-free diet; in a 1998 Finnish oat study the rash was not set off by eating oats (details under Monitoring and Long-Term Management).

Fewer new cases over time: DH is becoming less common even as celiac disease is diagnosed more often. In the Finnish 40-year study, new cases fell from 5.2 to 2.9 and then 2.7 per 100,000 people a year across three 10-year periods starting in 1980, a drop the authors contrasted with the rise in celiac disease. A 2018 review gives a yearly rate of 0.8 per 100,000 for the United Kingdom (U.K.).

Back to Table of Contents

Clinical Features and Symptoms

The clinical presentation of DH is distinctive but frequently misdiagnosed as eczema, scabies, or insect bites before the correct diagnosis is reached.

Pruritus as the defining symptom: DH produces one of the most intensely pruritic rashes in dermatology. The itch is characteristically described as burning and stinging rather than pure itch, and this burning sensation often precedes the appearance of visible lesions by hours. Patients frequently scratch lesions to the point of excoriation before they present to a physician, meaning intact vesicles are often absent at the time of clinical examination.

Primary lesion morphology: When intact, the primary lesion is a small tense vesicle (blister) arising on an erythematous base, grouped in clusters (hence "herpetiformis"). Papules and urticarial plaques also occur. Because vesicles are rapidly excoriated, the clinician more often sees:

Distribution: DH has a strikingly symmetric, extensor-predominant distribution:

The face and mucous membranes are rarely involved, distinguishing DH from pemphigus vulgaris. Palms and soles are generally spared.

Gastrointestinal involvement: Approximately 90% of DH patients have villous atrophy on duodenal biopsy — the same finding seen in classic celiac disease. However, only about 20% have overt gastrointestinal symptoms (diarrhea, bloating, abdominal pain). The majority of DH patients have subclinical celiac enteropathy: histological intestinal damage that is silent because the compensatory mucosal surface area of the small intestine masks nutritional deficiency. This fact is clinically important — a DH patient who denies gastrointestinal (GI) symptoms still has active celiac disease and still requires a gluten-free diet.

Nutritional consequences of silent celiac disease: Even without overt gastrointestinal symptoms, DH patients may present with iron-deficiency anemia (most common), folate deficiency, vitamin B12 deficiency (less common, as terminal ileum is usually spared), osteoporosis, and neurological sequelae.

Back to Table of Contents

Diagnostic Approach

The diagnosis of DH rests on skin biopsy with direct immunofluorescence (DIF). This is the gold-standard test. Serology provides supportive evidence and is useful for monitoring, but cannot substitute for histopathology in establishing the diagnosis.

Skin biopsy — site selection is critical: The biopsy is taken from perilesional skin — normal-appearing skin immediately adjacent to (within 1 cm of) an active lesion. Biopsy of the lesion itself is diagnostically unreliable: the blister and surrounding intense inflammation obscure the characteristic immunoglobulin A deposits and produce a nonspecific picture. Perilesional skin, which appears normal to the naked eye, harbors the diagnostic immunoglobulin A deposits without inflammatory artifact.

Direct immunofluorescence (DIF): The perilesional biopsy is processed in Michel's transport medium (not formalin) and examined by immunofluorescence microscopy. The pathognomonic finding is granular immunoglobulin A deposits in the dermal papillae. This granular (particulate) immunoglobulin A staining pattern distinguishes DH from Linear immunoglobulin A Bullous Dermatosis, which shows a linear band of immunoglobulin A at the dermoepidermal junction. Fibrin and C3 complement fragments are also commonly seen at papillary tips. Immunoglobulin G (IgG) and immunoglobulin M (IgM) deposits are absent or minimal.

Serology:

Duodenal biopsy: Gastroenterological evaluation with upper endoscopy and duodenal biopsy can demonstrate Marsh grade 2–3 villous atrophy, confirming the celiac enteropathy that underlies DH. Duodenal biopsy is not required for the DH diagnosis when DIF is positive and clinical presentation is consistent, but is often performed to document the extent of intestinal disease and to establish a baseline for monitoring.

Differential diagnosis:

Back to Table of Contents

Treatment: Gluten-Free Diet and Dapsone

Management of DH combines a disease-modifying dietary intervention (gluten-free diet) with a symptom-suppressing drug (dapsone) used as a bridge while the diet takes effect.

Gluten-Free Diet (GFD)

The GFD is the primary and definitive treatment for DH. It is the only intervention that addresses both the skin disease and the underlying intestinal celiac damage simultaneously. Key points:

Dapsone (Diaminodiphenyl Sulfone)

Dapsone is the primary pharmacological therapy for DH. It produces dramatic symptomatic relief but does not modify the underlying disease:

Alternative Agents for Dapsone-Intolerant Patients

When dapsone is contraindicated (glucose-6-phosphate dehydrogenase deficiency, allergy, intolerance), alternatives include:

Topical steroids and antihistamines provide minimal relief for the intense itch of DH and are not considered adequate monotherapy.

Back to Table of Contents

Monitoring and Long-Term Management

DH requires lifelong management because the underlying gluten sensitivity does not resolve. With sustained strict dietary adherence, however, most patients achieve complete skin remission and significantly reduce their cancer risk.

Laboratory monitoring:

Long-term cancer risk: Untreated or poorly controlled celiac disease — including the subclinical celiac disease of DH — is associated with a modestly elevated risk of lymphoma (a cancer of the immune cells). In a Finnish study of 1,104 people diagnosed with DH between 1969 and 2001, 11 (1%) developed lymphoma 2–31 years after diagnosis. Most were B-cell lymphomas (8 of the 11); 2 were enteropathy-associated T-cell lymphoma (EATL), the lymphoma most linked with celiac disease, which arises from chronically activated intraepithelial T lymphocytes in the setting of persistent gut inflammation; 1 could not be classified. The absolute risk of this lymphoma is low (estimated 5–7 per 100,000 patient-years), but it is meaningfully higher than the general population. Sustained strict gluten-free diet appears to reduce this risk to background levels. The 11 patients with lymphoma had kept to the gluten-free diet significantly less strictly than matched DH patients without lymphoma. Among 1,825 of the patients' parents, siblings and children, 3 (0.2%) developed lymphoma, all B-cell type. A 2018 Finnish review reported that the long-term outlook of DH patients on a gluten-free diet is excellent, with a death rate even lower than that of the general population. Non-responsive or refractory disease is the setting in which gastroenterologists carry out endoscopic checks of gut healing and look for lymphoma.

A 2026 United States study: Researchers using a large U.S. health-records database compared 6,896 adults with DH (average age 53) identified between 2005 and 2025 with matched people who had neither celiac disease nor DH. During follow-up 8.36% of the DH group died against 6.54% of the comparison group (adjusted hazard ratio 1.25). The DH group also had more major heart and blood-vessel events (hazard ratio 1.22) and about 2.6 times the rate of non-Hodgkin lymphoma (hazard ratio 2.58). The study abstract does not report the results by whether people kept a gluten-free diet.

Pregnancy and DH: DH can worsen, improve, or remain unchanged during pregnancy. The GFD is continued through pregnancy. Dapsone was listed as U.S. Food and Drug Administration (FDA) pregnancy category C under the older letter system, which the FDA has since replaced in drug labels with a written risk summary; it is often continued during pregnancy when the benefit is judged to outweigh the risk, with obstetric care involved. Dapsone exposure before birth can cause hemolytic anemia in the newborn, which is why exposed newborns are checked for it.

Children and adolescents: DH in children requires particularly attentive dietary counseling, as school environments (cafeterias, shared snacks) create constant cross-contamination risk. Untreated celiac enteropathy significantly slows growth, which is why children's growth and nutrition are tracked closely.

Reintroduction of oats: In practice, certified gluten-free oats are usually introduced cautiously after at least 1–2 years of stable, well-controlled disease on a GFD, under supervision, with clinical reassessment at 6 months. In a 1998 Finnish study, 11 DH patients in remission on a gluten-free diet ate 50 g of oats every day for six months: 8 stayed free of symptoms, 2 had a short-lived rash and 1 left the study because of a mild but more lasting rash. Three of 11 comparison patients who ate no oats also had a short-lived rash. A blood marker of celiac activity (IgA endomysial antibodies) stayed negative in everyone, and biopsies showed no change in the small-bowel lining. The authors concluded that the rash in DH is not set off by eating oats. The main gluten risk with oats comes from wheat, barley or rye mixed in with ordinary oats, not from the oats themselves.

Back to Table of Contents

Key Research Papers

  1. Bolotin D, Petronic-Rosic V. "Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation." J Am Acad Dermatol. 2011;64(6):1017–1024. — PubMed PMID: 21571167
  2. Antiga E, Caproni M. "The diagnosis and treatment of dermatitis herpetiformis." Clin Cosmet Investig Dermatol. 2015;8:257–265. — PubMed PMID: 25999753
  3. Reunala T, Salmi TT, Hervonen K, et al. "Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease." Nutrients. 2018;10(5):602. — PubMed PMID: 29757210
  4. Salmi TT, Hervonen K, Kautiainen H, et al. "Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study." Br J Dermatol. 2011;165(2):354–359. — PubMed PMID: 21517799
  5. Zone JJ. "Skin manifestations of celiac disease." Gastroenterology. 2005;128(4 Suppl 1):S87–91. — PubMed PMID: 15825132
  6. Caproni M, Antiga E, Melani L, et al. "Guidelines for the diagnosis and treatment of dermatitis herpetiformis." J Eur Acad Dermatol Venereol. 2009;23(6):633–638. — PubMed PMID: 19470076
  7. Hervonen K, Hakanen M, Kaukinen K, et al. "First-degree relatives are frequently affected in coeliac disease and dermatitis herpetiformis." Scand J Gastroenterol. 2002;37(1):51–55. — PubMed PMID: 11843035
  8. Reunala T, Collin P, Holm K, et al. "Tolerance to oats in dermatitis herpetiformis." Gut. 1998;43(4):490–493. — PubMed PMID: 9824575
  9. Sugai E, Vazquez H, Nachman F, et al. "Accuracy of testing for antibodies to synthetic gliadin-related peptides in celiac disease." Clin Gastroenterol Hepatol. 2006;4(9):1112–1117. — PubMed PMID: 16860613
  10. Fry L, Seah PP, Harper PG, et al. "The small intestine in dermatitis herpetiformis." J Clin Pathol. 1974;27(10):817–824. — PubMed PMID: 4426977
  11. Collin P, Reunala T, Rasmussen M, et al. "High incidence and prevalence of adult coeliac disease. Augmented diagnostic approach." Scand J Gastroenterol. 1997;32(11):1129–1133. — PubMed PMID: 9399394
  12. Sárdy M, Kárpáti S, Merkl B, et al. "Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis." J Exp Med. 2002;195(6):747–757. — PubMed PMID: 11901200
  13. Hervonen K, Vornanen M, Kautiainen H, Collin P, Reunala T. "Lymphoma in patients with dermatitis herpetiformis and their first-degree relatives." Br J Dermatol. 2005;152(1):82–86. — PubMed PMID: 15656805
  14. Ludvigsson JF, Dagher J, Lebwohl B, Yao J, Green PHR, Ludwig RJ, Curman P. "Mortality, cardiovascular disease, and cancer in coeliac disease and dermatitis herpetiformis: a matched cohort study." Lancet Reg Health Am. 2026;60:101512. — PubMed PMID: 42256615

Back to Table of Contents

Related PubMed Searches

  1. Dermatitis herpetiformis treatment
  2. Dermatitis herpetiformis dapsone gluten-free diet
  3. Dermatitis herpetiformis immunoglobulin A direct immunofluorescence diagnosis
  4. Epidermal transglutaminase TG3 dermatitis herpetiformis
  5. Celiac disease skin manifestations autoimmune

Back to Table of Contents


Back to Table of Contents

Connections

Back to Table of Contents